Three Lakes Foundation News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Bridge to join as an industry member to advance the science of early detection and speed development of novel treatments SEONGNAM, South Korea and CAMBRIDGE, Mass., July 12, 2023 /PRNewswire/ -- Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotech company developing novel drugs for fibrosis, cancer and inflammation, announced that it has joined PROLIFIC, the Prognostic Lung Fibrosis Consortium,...

/PRNewswire/ -- Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotech company developing novel drugs for fibrosis, cancer and inflammation,...

A steering committee of pulmonary experts and primary care physicians (PCPs) released today a white paper outlining the issues surrounding delays in diagnosing interstitial lung diseases (ILDs) like pulmonary fibrosis (PF).

The rise of lung scarring signs like shortness of breath alongside COVID-19 had made the condition more difficult to diagnose.

The American College of Chest Physicians (CHEST) and Three Lakes Foundation are announcing a steering committee of experts in the fields of pulmonary medicine and primary care medicine to lead an initiative called Bridging Specialties™: Timely Diagnosis for ILD Patients.